Design, synthesis and pharmacological evaluation of novel 4-phenoxyquinoline derivatives as potential antitumor agents

Abstract

A series of novel 4-phenoxyquinoline derivatives containing 3-amino-2-cyano-acrylamide framework was designed and synthesized, and the in vitro cytotoxic activities of them against five cancer cell lines(HT-29, H460, A549, MKN-45, and U87MG) were evaluated. Most of the compounds exhibited moderate-to-significant cytotoxicity and high selectivity against one or more cell lines as compared with Foretinib. The studies of their preliminary structure-activity relationships(SARs) indicate that the compounds containing methyl groups, especially methyl groups at 4-position of the phenyl ring(moiety B) are more effective. Among them, compound 36 shows the most potent antitumor activities with IC₅₀ values of 0.04, 0.09, 0.67, 0.39 and 1.10 μmol/L against HT-29, H460, A549, MKN-45 and U87MG cell lines, respectively.

Keywords

4-Phenoxyquinoline derivative / Cytotoxic activity / 3-Amino-2-cyano-acrylamide

References

[1] Bottaro D. P., Rubin J. S., Faletto D. L., Chan A. M., Kmiecik T. E., Vande Woude G. V., Aaronson S. A. Science, 1991, 251: 802.

[2] Yu H. Y., Tang Z. H., Song W. T., Deng M. X., Chen X. S. Chem. J. Chinese. Universitie, 2014, 35(5): 903.

[3] Wang S. Y., Chen B., Zhan Y. Q., Xu W. X., Li C. Y., Yang R. F., Zheng H., Yue P. B., Larsen S. H., Sun H. B., Yang X. M. Journal of Hepatolog, 2004, 41: 267.

[4] Corso S., Comoglio P. M., Giordano S. Trends Mol. Med., 2005, 11: 284.

[5] Riccardo F., Martina O., Maria F. D. R., Marina M., Carla D. G., Patrizia N., Giuseppe B., Katia S., Pier-Luigi L., Comoglio P. M. Oncogene, 1996, 12: 1697.

[6] Francesca D. B., Michela F., Andrea R. Cancer Ther., 2004, 213: 317.

[7] Underiner L. T., Herbertz T., Miknyoczki J. S. Anticancer Agent Med., 2010, 10: 7.

[8] Yakes F. M., Chen J., Tan J., Yamaguchi K., Shi Y. C., Yu P. W., Qian F., Chu F., Bentzien F., Cancilla B., Orf J., You A., Laird A. D., Engst S., Lee L., Lesch J., Chou Y. C., Joly A. H. Mol. Cancer Ther., 2011, 10: 2298.

[9] Kim K. S., Zhang L., Shmidt R., Cai Z. W., Wei D., Williams D. K., Lombardo L. J., Trainor G. L., Xie D., Zhang Y., An Y., Sack J. S., Tokarski J. S., Darienzo C., Kamath A., Marathe P., Zhang Y., Lippy J., Jeyaseelan R., Wautlet B., Henley B., Gullo-Brown J., Manne V., Hunt J. T., Fargoli J., Borzilleri R. M. J. Med. Chem., 2008, 51: 5330.

[10] Norman M. H., Liu L. B., Lee M., Xi N., Fellows I., D’Angelo N. D., Dominguez C., Rex K., Bellon S. F., Kim T. S., Dussault I. J. Med. Chem., 2012, 55: 1858.

[11] Liu L. B., Norman M. H., Lee M., Xi N., Siegmund A., Boezio A. A., Booker S., Choquette D., D’Angelo N. D., Germain J., Yang K., Yang Y. J., Zhang Y. H., Bellon S. F., Whittington D. A., Harmange J. C., Dominguez C., Kim T. S., Dussault I. J. Med. Chem., 2012, 55: 1868.

[12] Zhai X., He Y., Yang Z., Gong P. Chem. Res. Chinese. Universities, 2013, 29(1): 62.

[13] Li S., Huang Q., Liu Y. J., Zhang X. L., Liu S., He C., Gong P. Eur. J. Med. Chem., 2013, 64: 62.

[14] Qi B. H., Tao H. Y., Wu D., Bai J. Y., Shi Y. D., Gong P. Arch. harm. Chem. Life Sci., 2013, 346: 596.

[15] Qi B. H., Mi B., Zhai X., Xu Z. Y., Zhang X. L., Tian Z. R., Gong P. Bioorg. Med. Chem., 2013, 21: 5246.

[16] Li S., Zhao Y. F., Wang K. W., Gao Y. L., Han J. M., Cui B. B., Gong P. Bioorg. Med. Chem., 2013, 21: 2843.

[17] Li S., Jiang R., Qin M. Z., Liu H. C., Zhuang G. Y., Gong P. Arch. harm. Chem. Life Sci., 2013, 346: 521.

[18] Tang Q. D., Zhao Y. F., Du X. M., Chong L. E., Gong P., Guo C. Eur. J. Med. Chem., 2013, 69: 77.

[19] Tang Q. D., Zhang G. G., Du X. M., Zhu W. F., Li R. J., Lin H. F., Li P. C., Cheng M. S., Gong P., Zhao Y. F. Bioorg. Med. Chem., 2014, 22: 1236.

[20] Zhou S. G., Liao H. M., Liu M. M., Feng G. B., Fu B. L., Li R. J., Cheng M. S., Zhao Y. F., Gong P. Bioorg. Med. Chem., 2014, 22: 6438.

[21] George R. F. Eur. J. Med. Chem., 2012, 47: 377.

[22] Moustafa A. G., Abu-Hashem A. A. Arch. Pharm. Chem. Life Sci., 2011, 11: 170.

[23] Bellon S. F., Kaplan-Lefko P., Yang Y. J., Zhang Y. H., Moriguchi J., Rex K., Johnson C. W., Rose P. E., Long A. M., O’Connor A. B., Gu Y., Coxon A., Kim T. S., Tasker A., Burgess T. L., Dussault I. J. Biol. Chem., 2008, 283: 2675.

[24] Gong P., Liu Y. J., Zhao Y. F., Zhai X. Quinoline and Cinnoline Compounds as c-Met Kinase Inhibitors and Their Preparation, harmaceutical Compositions and Use in the Treatment of Hyperplastic Diseases, 2012.

[25] Hernández S., Moreno I., San M. R., Gómez G., Herrero M. T., Domínguez E. J. Org. Chem., 2010, 75: 434.